Ikarian Capital’s Immunic IMUX Stock Holding History

Ikarian Capital’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Sell	67,464 -2	-0%	-$25	0.11%	103
2026 Q1	$749K	Hold	67,466	–	–	0.06%	116
2025 Q4	$360K	Sell	67,466 -23,951	-26%	-$175K	0.03%	143
2025 Q3	$806K	Hold	91,417	–	–	0.08%	126
2025 Q2	$638K	Hold	91,417	–	–	0.12%	87
2025 Q1	$996K	Sell	91,417 -70,000	-43%	-$756K	0.12%	99
2024 Q4	$1.61M	Buy	161,417 +112,067	+227%	+$1.41M	0.22%	89
2024 Q3	$814K	Hold	49,350	–	–	0.11%	106
2024 Q2	$548K	Sell	49,350 -111,888	-69%	-$1.39M	0.1%	92
2024 Q1	$2.13M	Buy	+161,238	New	+$2.1M	0.23%	86
2023 Q4	–	Sell	-45,000	Closed	-$551K	–	153
2023 Q3	$662K	Sell	45,000 -20,000	-31%	-$384K	0.08%	105
2023 Q2	$1.63M	Hold	65,000	–	–	0.26%	73
2023 Q1	$969K	Hold	65,000	–	–	0.22%	82
2022 Q4	$910K	Buy	+65,000	New	+$1.77M	0.22%	52
2022 Q3	–	Sell	-6,150	Closed	-$214K	–	132
2022 Q2	$214K	Buy	+6,150	New	+$394K	0.04%	118

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Ikarian Capital's IMUX Position: Q2 2026 in Review

Ikarian Capital reduced its Immunic (IMUX) stake by 0% in Q2 2026, selling an estimated $25 and leaving 67,464 shares worth $1.04M. The position accounts for 0.11% of the portfolio, ranked #103.

Ikarian Capital first reported a position in IMUX in Q2 2022 and has held it in 15 quarters since. The position peaked at $2.13M in Q1 2024. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Ikarian Capital held 67,464 shares of Immunic worth $1.04M as of Q2 2026.
Ikarian Capital sold 2 Immunic shares in Q2 2026, an estimated $25.
Immunic made up 0.11% of Ikarian Capital's portfolio in Q2 2026, its #103 holding.
Ikarian Capital first reported a position in Immunic in Q2 2022 and has held it in 15 quarters since.
Ikarian Capital's Immunic position peaked at $2.13M in Q1 2024.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.